# DURGA-6 (NCT07735637)

> A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07735637
- Phase: PHASE3
- Status: NOT_YET_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions: AZD0120; Cyclophosphamide; Fludarabine; Melphalan (part of ASCT); Lenalidomide
- Enrollment: 750
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)

## Commentary we found

- X threads: 4
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=durga-6-nct07735637